Compare ARK Genomic Revolution ETF (ARKG) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Delta Air Lines, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.32, while Delta Air Lines, Inc. trades at $86.28 (market cap $57.41B). The key difference: Delta Air Lines, Inc. pays a 0.89% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | DAL | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $93.66 |
52-Week Low | $23.09 | $51.15 |
Market Cap | — | $57.41B |
Enterprise Value | — | $72.73B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Delta Air Lines (DAL) trades at $87.39, down 1.81% today, but maintains a bullish technical outlook with strong support at $86. The company reported Q2 2026 EPS of $2.45, beating estimates by 64%, driven by premium demand and World Cup traffic benefits. Revenue growth remains robust at 14% year-over-year, with a net income margin of 6.87%. Analysts are overwhelmingly bullish with an 82% buy rating and a $106.07 price target, implying 21% upside. Cash flow trends show consistent operational strength, with 2025 net cash flow at $1.08 billion.
DAL presents a compelling investment case with earnings momentum, reasonable valuation (P/E 14.49), and analyst confidence. Key risks include fuel cost volatility and competitive pricing pressure, but strong corporate travel demand and dividend growth support long-term value. The stock's current dip offers a potential entry point near technical support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
